Equities analysts expect Heska Corporation (NASDAQ:HSKA) to report sales of $35.65 million for the current quarter, Zacks reports. Two analysts have made estimates for Heska Corporation’s earnings, with the highest sales estimate coming in at $35.81 million and the lowest estimate coming in at $35.49 million. Heska Corporation posted sales of $33.43 million in the same quarter last year, which suggests a positive year over year growth rate of 6.6%. The company is expected to issue its next earnings report before the market opens on Thursday, November 2nd.
On average, analysts expect that Heska Corporation will report full-year sales of $35.65 million for the current year, with estimates ranging from $142.08 million to $144.00 million. For the next financial year, analysts anticipate that the business will post sales of $158.83 million per share, with estimates ranging from $157.34 million to $159.64 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Heska Corporation.
Heska Corporation (NASDAQ:HSKA) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.07. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The company had revenue of $34.30 million for the quarter, compared to analysts’ expectations of $33.35 million. During the same period last year, the firm earned $0.35 earnings per share. Heska Corporation’s quarterly revenue was up 14.3% on a year-over-year basis.
A number of brokerages have commented on HSKA. BidaskClub lowered shares of Heska Corporation from a “buy” rating to a “hold” rating in a report on Monday, August 14th. Benchmark Co. boosted their price objective on shares of Heska Corporation from $106.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. Canaccord Genuity began coverage on shares of Heska Corporation in a report on Thursday, October 5th. They issued a “buy” rating and a $115.00 price objective on the stock. B. Riley reiterated a “neutral” rating and issued a $96.50 price objective on shares of Heska Corporation in a report on Thursday, August 3rd. Finally, Zacks Investment Research lowered shares of Heska Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Heska Corporation presently has an average rating of “Hold” and an average price target of $106.83.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/11/analysts-expect-heska-corporation-hska-will-post-quarterly-sales-of-35-65-million.html.
In other news, EVP Nancy Wisnewski sold 825 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $102.21, for a total value of $84,323.25. Following the sale, the executive vice president now owns 38,114 shares in the company, valued at approximately $3,895,631.94. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO John Mcmahon sold 2,608 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $101.17, for a total transaction of $263,851.36. Following the completion of the sale, the chief financial officer now owns 193 shares in the company, valued at approximately $19,525.81. The disclosure for this sale can be found here. Corporate insiders own 14.70% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Victory Capital Management Inc. acquired a new stake in shares of Heska Corporation in the 1st quarter valued at about $101,000. Royal Bank of Canada raised its stake in shares of Heska Corporation by 96.9% in the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock valued at $103,000 after purchasing an additional 499 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of Heska Corporation in the 2nd quarter valued at about $127,000. LS Investment Advisors LLC raised its stake in shares of Heska Corporation by 411.2% in the 2nd quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock valued at $130,000 after purchasing an additional 1,028 shares in the last quarter. Finally, Mason Street Advisors LLC acquired a new stake in shares of Heska Corporation in the 1st quarter valued at about $144,000. Institutional investors and hedge funds own 80.47% of the company’s stock.
Heska Corporation (HSKA) traded down 0.14% during mid-day trading on Friday, reaching $96.63. The company’s stock had a trading volume of 3,258 shares. The stock has a market capitalization of $698.25 million, a P/E ratio of 49.25 and a beta of 0.84. The stock’s 50 day moving average price is $93.88 and its 200 day moving average price is $97.98. Heska Corporation has a 1-year low of $46.51 and a 1-year high of $115.00.
About Heska Corporation
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Get a free copy of the Zacks research report on Heska Corporation (HSKA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.